Translational genomics of ovarian clear cell carcinoma

Semin Cancer Biol. 2020 Apr;61:121-131. doi: 10.1016/j.semcancer.2019.10.025. Epub 2019 Nov 4.


Ovarian clear cell carcinomas (OCCC) are rare aggressive, chemo-resistant tumours comprising approximately 13% of all epithelial ovarian cancers, which have distinct clinical and molecular features, when compared to other gynaecological malignancies. At present, there are no specific licensed targeted therapies for OCCC, although a number of candidate targets have been identified. This review focuses on recent knowledge underpinning our understanding of the pathogenesis of OCCC including direct and synthetic-lethal therapeutic strategies in particular focussing on ARID1A deficiency. We also discuss current targeted clinical trials and immunotherapeutic approaches.

Keywords: ARID1A; Endometriosis; Immunotherapy; Ovarian clear cell; Targeted therapies.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adenocarcinoma, Clear Cell / diagnosis
  • Adenocarcinoma, Clear Cell / etiology*
  • Adenocarcinoma, Clear Cell / metabolism
  • Adenocarcinoma, Clear Cell / therapy
  • Biomarkers
  • Carcinoma, Ovarian Epithelial / diagnosis
  • Carcinoma, Ovarian Epithelial / etiology*
  • Carcinoma, Ovarian Epithelial / metabolism
  • Carcinoma, Ovarian Epithelial / therapy
  • DNA Copy Number Variations
  • DNA-Binding Proteins / genetics
  • Disease Management
  • Epigenesis, Genetic
  • Female
  • Genetic Association Studies
  • Genetic Predisposition to Disease
  • Genomics* / methods
  • Humans
  • Mutation
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / genetics
  • Neovascularization, Pathologic / metabolism
  • Signal Transduction
  • Transcription Factors / genetics
  • Translational Research, Biomedical*


  • ARID1A protein, human
  • Biomarkers
  • DNA-Binding Proteins
  • Transcription Factors